Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

On February 27, 2026, Fulgent reported its fourth quarter and full year 2025 financial results. The Company disclosed that full year 2025 revenue was approximately $322.7 million, which fell slightly short of the updated guidance previously provided. Fulgent also reported that fourth quarter revenue declined sequentially.

If you suffered a loss in the Company securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys Andrea Farah at (914) 733-7256 or via email to afarah@lowey.com or Vincent R. Cappucci Jr. at (914) 733-7278 or via email at vcappucci@lowey.com.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: investigations@lowey.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.